
Opinion|Videos|November 23, 2023
The Role of TROP2 as a Biomarker in NSCLC
Author(s)Anne S. Tsao, MD, Edward B. Garon, MD, MS
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, provide an overview of TROP2 as a target for patients with non–small cell lung cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
4
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
5







































